Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-Arm, Phase 2 Trial of Stereotactic Radiotherapy for Patients With Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

NCT04764214 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04764214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04764214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-Arm, Phase 2 Trial of Stereotactic Radiotherapy for Patients With Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2021
Completion date
July 20, 2023
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, nsclc stage iv